JP2019522973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522973A5 JP2019522973A5 JP2018567062A JP2018567062A JP2019522973A5 JP 2019522973 A5 JP2019522973 A5 JP 2019522973A5 JP 2018567062 A JP2018567062 A JP 2018567062A JP 2018567062 A JP2018567062 A JP 2018567062A JP 2019522973 A5 JP2019522973 A5 JP 2019522973A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen recognition
- domain
- recognition domain
- receptor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 45
- 102000036639 antigens Human genes 0.000 claims 45
- 108091007433 antigens Proteins 0.000 claims 45
- 210000004027 cell Anatomy 0.000 claims 34
- -1 NY-ES0-1 Proteins 0.000 claims 20
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 15
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 15
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 14
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 14
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 12
- 102000010956 Glypican Human genes 0.000 claims 12
- 108050001154 Glypican Proteins 0.000 claims 12
- 108050007237 Glypican-3 Proteins 0.000 claims 12
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 11
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 9
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 9
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 9
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 9
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 9
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 9
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 9
- 102100035721 Syndecan-1 Human genes 0.000 claims 9
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 8
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 8
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 8
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 7
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 102100022749 Aminopeptidase N Human genes 0.000 claims 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 6
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 6
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 6
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
- 102100032999 Integrin beta-3 Human genes 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 102100025136 Macrosialin Human genes 0.000 claims 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 6
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 5
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 5
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 4
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 4
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 4
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2016/039306 | 2016-06-24 | ||
| PCT/US2016/039306 WO2016210293A1 (en) | 2015-06-25 | 2016-06-24 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| US201662369004P | 2016-07-29 | 2016-07-29 | |
| US62/369,004 | 2016-07-29 | ||
| PCT/US2016/068349 WO2017222593A1 (en) | 2016-06-24 | 2016-12-22 | Chimeric antigen receptors (cars), compositions and methods thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522973A JP2019522973A (ja) | 2019-08-22 |
| JP2019522973A5 true JP2019522973A5 (enExample) | 2020-02-06 |
| JP7114490B2 JP7114490B2 (ja) | 2022-08-08 |
Family
ID=60783276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567062A Active JP7114490B2 (ja) | 2016-06-24 | 2016-12-22 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20200283534A1 (enExample) |
| EP (2) | EP4353750A3 (enExample) |
| JP (1) | JP7114490B2 (enExample) |
| CN (1) | CN109562126A (enExample) |
| CA (1) | CA3029197A1 (enExample) |
| WO (1) | WO2017222593A1 (enExample) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3240805B1 (en) | 2014-12-15 | 2024-11-27 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP4134430A1 (en) | 2015-02-06 | 2023-02-15 | National University of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| SG10201913682QA (en) * | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| US20220348633A1 (en) * | 2015-06-25 | 2022-11-03 | Icell Gene Therapeutics Llc | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF |
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| MX2018005315A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| US11384156B2 (en) * | 2016-07-25 | 2022-07-12 | The Nemours Foundation | Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| KR20190057308A (ko) | 2016-09-02 | 2019-05-28 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물 |
| US20190352409A1 (en) * | 2016-11-11 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| AU2018207300B2 (en) * | 2017-01-10 | 2023-08-24 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| WO2018160768A1 (en) | 2017-02-28 | 2018-09-07 | Vor Biopharma, Inc. | Compositions and methods for inhibition lineage specific proteins |
| JP2020516654A (ja) | 2017-04-13 | 2020-06-11 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| AU2018251206A1 (en) * | 2017-04-14 | 2019-10-31 | The General Hospital Corporation | Chimeric antigen receptor T cells targeting the tumor microenvironment |
| CA3060443A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11622977B2 (en) | 2017-05-12 | 2023-04-11 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| EP3649147A4 (en) | 2017-07-03 | 2021-04-14 | Torque Therapeutics, Inc. | POLYNUCLEOTIDES CODING IMMUNOSTIMULANT FUSION MOLECULES AND THEIR USES |
| CN111183156A (zh) | 2017-07-31 | 2020-05-19 | 莱蒂恩技术公司 | 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法 |
| CA3071282A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| WO2019084240A1 (en) | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF TREATING CANCER USING RADIO-labeled CD45 ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELLULAR THERAPIES |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| DK3703750T3 (da) | 2017-11-01 | 2025-02-10 | Juno Therapeutics Inc | Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN111655732B (zh) | 2017-11-14 | 2023-09-12 | Gc细胞治疗 | 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体 |
| EP3512874A2 (en) * | 2017-11-30 | 2019-07-24 | Grifols Diagnostic Solutions Inc. | Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1 |
| JP7566628B2 (ja) * | 2018-01-10 | 2024-10-15 | ザ ジェネラル ホスピタル コーポレイション | キメラ抗原受容体を発現する免疫細胞 |
| CN108314738B (zh) * | 2018-01-29 | 2020-09-08 | 山东兴瑞生物科技有限公司 | 一种共表达细胞因子il-21的双特异性嵌合抗原受体、质粒、cik细胞及mm病应用 |
| CA3089170A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US20200399383A1 (en) * | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| EP3752601A4 (en) * | 2018-02-15 | 2022-03-23 | Memorial Sloan-Kettering Cancer Center | FOXP3-TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| CN112955184A (zh) * | 2018-03-15 | 2021-06-11 | 基本解决方案公司 | 可编程免疫细胞受体复合物系统 |
| CA3089333C (en) | 2018-03-26 | 2023-10-10 | Altor Bioscience Llc | Anti-pdl1, il-15 and tgf-beta receptor combination molecules |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019199793A1 (en) * | 2018-04-09 | 2019-10-17 | Mayo Foundation For Medical Education And Research | Methods and materials for treating graft-versus-host disease |
| AU2019252944B2 (en) * | 2018-04-12 | 2022-12-08 | Kite Pharma, Inc. | Chimeric receptor T cell treatment using characteristics of the tumor microenvironment |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| US12473342B2 (en) | 2018-04-27 | 2025-11-18 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis |
| WO2019210293A1 (en) * | 2018-04-27 | 2019-10-31 | Baylor College Of Medicine | Car t cells with one or more interleukins |
| CN110468105B (zh) * | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | 表达il-18r结合蛋白的免疫效应细胞 |
| IL278348B2 (en) | 2018-05-11 | 2025-03-01 | Crispr Therapeutics Ag | Methods and preparations for treating cancer |
| CA3103610A1 (en) | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| BR112020025439A2 (pt) | 2018-06-14 | 2021-03-16 | Bluebird Bio, Inc. | Receptores de antígenos quiméricos cd79a |
| WO2019246593A2 (en) * | 2018-06-22 | 2019-12-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
| WO2020009868A1 (en) | 2018-07-03 | 2020-01-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-slamf7 chimeric antigen receptors |
| CN108864307A (zh) * | 2018-07-23 | 2018-11-23 | 北京多赢时代科技有限公司 | 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用 |
| US20210079111A1 (en) * | 2018-08-04 | 2021-03-18 | AbCyte Therapeutics Inc. | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof |
| CN110862967A (zh) * | 2018-08-27 | 2020-03-06 | 天津天锐生物科技有限公司 | 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk |
| MX2021002415A (es) | 2018-08-28 | 2021-09-21 | Vor Biopharma Inc | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. |
| EP3845654A4 (en) * | 2018-08-31 | 2022-05-11 | Noile-Immune Biotech, Inc. | Car-expressing t cells and car expression vector |
| AU2019335014A1 (en) * | 2018-09-05 | 2021-03-25 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| JP2022501067A (ja) * | 2018-09-26 | 2022-01-06 | 上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. | Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用 |
| CN110950965B (zh) * | 2018-09-26 | 2021-10-15 | 重庆精准生物技术有限公司 | 抗人cd123的嵌合抗原受体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3864142A4 (en) * | 2018-10-12 | 2023-07-19 | iCell Gene Therapeutics LLC | CHEMERA ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| US10993967B2 (en) * | 2018-10-17 | 2021-05-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| JP7742773B2 (ja) * | 2018-11-01 | 2025-09-22 | ジュノー セラピューティクス インコーポレイテッド | Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体 |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| WO2020113054A1 (en) | 2018-11-30 | 2020-06-04 | Mustang Bio, Inc. | Methods of treatment using decitabine and a cd123-targeted therapy |
| WO2020124021A1 (en) * | 2018-12-13 | 2020-06-18 | The General Hospital Corporation | Chimeric antigen receptors targeting cd79b and cd19 |
| SG11202106952UA (en) | 2018-12-24 | 2021-08-30 | Haidong Huang | Recombinant human 2ig-b7-h3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof |
| JP2022524178A (ja) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| EP3917313A4 (en) * | 2019-02-01 | 2023-02-08 | Actinium Pharmaceuticals, Inc. | ANTI-CD45 MOLECULES AND DERIVATIVES THEREOF |
| SG11202109057XA (en) * | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| EP3954762A4 (en) | 2019-03-28 | 2023-01-18 | Korea Research Institute of Bioscience and Biotechnology | METHOD FOR PRODUCTION OF NK CELLS WITH A CAR GENE INTRODUCED THEREOF, AND USE THEREOF |
| WO2020210719A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Management, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| CN110055281B (zh) * | 2019-04-25 | 2020-09-01 | 山东大学第二医院 | 一种用于制备car-t的慢病毒载体及其构建方法和应用 |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| KR20220016083A (ko) * | 2019-04-30 | 2022-02-08 | 센티 바이오사이언시스, 인코포레이티드 | 키메라 수용체 및 이의 사용 방법 |
| WO2020223535A1 (en) * | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| EP3747904A1 (en) * | 2019-06-03 | 2020-12-09 | Universität Regensburg | Cd25-specific chimeric antigen receptors and their uses |
| US20200384029A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| EP3983445A4 (en) * | 2019-06-14 | 2023-06-21 | 2seventy bio, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| WO2020263484A1 (en) * | 2019-06-28 | 2020-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| US12428476B2 (en) | 2019-07-11 | 2025-09-30 | Valkyr, Inc. | System and methods relating to chimeric autoantibody receptors |
| EP3999082A4 (en) * | 2019-07-17 | 2022-11-30 | National University of Singapore | Functional binders synthesized and secreted by immune cells |
| CN110452294B (zh) | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
| US20220324987A1 (en) * | 2019-08-28 | 2022-10-13 | Montefiore Medical Center | Cd25 chimeric antigen receptors and uses thereof |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| WO2021064718A1 (en) * | 2019-10-01 | 2021-04-08 | Case Western Reserve University | Targeting b cell activating factor receptor (baff-r) using ligand-based chimeric antigen receptor (car)-t cells |
| CA3153441A1 (en) * | 2019-10-01 | 2021-04-08 | Reshmi Parameswaran | Targeting b cell activating factor receptor (baff-r) using ligand-based chimeric antigen receptor (car)-t cells |
| EP4041297A4 (en) | 2019-10-11 | 2024-02-28 | The Trustees of The University of Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING CD13 AND TIM-3 WITH CAR-T CELLS FOR TREATING ACUTE MYELOID LEUKEMIA |
| TWI717880B (zh) | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| CA3160759A1 (en) * | 2019-12-05 | 2021-06-10 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
| JP7781761B2 (ja) * | 2020-02-27 | 2025-12-08 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| CN111411085A (zh) * | 2020-04-10 | 2020-07-14 | 格源致善(上海)生物科技有限公司 | 一种嵌合抗原受体t细胞及其应用 |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| CN115777017A (zh) * | 2020-05-06 | 2023-03-10 | 亘喜生物科技（上海）有限公司 | 用于t细胞工程改造的组合物及方法 |
| KR20230029621A (ko) | 2020-05-08 | 2023-03-03 | 알파인 이뮨 사이언시즈, 인코포레이티드 | T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법 |
| US20230338531A1 (en) * | 2020-08-20 | 2023-10-26 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
| AU2021334950A1 (en) * | 2020-08-24 | 2023-03-02 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (CAR)-expressing cells recognizing CEA |
| EP4211230A4 (en) * | 2020-09-08 | 2025-01-15 | Gracell Biotechnologies (Shanghai) Co., Ltd. | COMPOSITIONS AND METHODS FOR MODIFICATION OF T CELLS |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| CN116783283A (zh) * | 2020-11-13 | 2023-09-19 | Gpb科学有限公司 | 产生具有增加的核酸摄取的细胞群体的方法 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| JP2023553419A (ja) | 2020-12-03 | 2023-12-21 | センチュリー セラピューティクス，インコーポレイテッド | 遺伝子操作細胞およびその使用 |
| US20220195396A1 (en) * | 2020-12-03 | 2022-06-23 | Century Therapeutics, Inc. | Genetically Engineered Cells and Uses Thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| CN115786271B (zh) * | 2021-01-12 | 2025-07-22 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| CN112778427B (zh) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | 双特异性cs1-bcma car-t细胞及其应用 |
| US20220267423A1 (en) * | 2021-02-22 | 2022-08-25 | IgGenix, Inc. | Ige antibodies cross-reactive to allergens and tumor antigens |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| WO2022234976A1 (ko) * | 2021-05-04 | 2022-11-10 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR102671411B1 (ko) * | 2021-05-11 | 2024-06-04 | 진화섭 | Baff 세포외 도메인을 포함하는 키메릭 항원 수용체 및 이의 용도 |
| CN115340610A (zh) * | 2021-05-12 | 2022-11-15 | 珠海市丽珠单抗生物技术有限公司 | 双特异性car t细胞及其应用 |
| CN113501884B (zh) * | 2021-06-30 | 2022-03-22 | 徐州医科大学 | 靶向B7H3的全人源嵌合抗原受体、iNKT细胞及其用途 |
| CN113549158B (zh) * | 2021-07-19 | 2022-10-21 | 广州百暨基因科技有限公司 | 包含突变型il15以及嵌合抗原受体的融合蛋白 |
| EP4376876A1 (en) * | 2021-07-26 | 2024-06-05 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| WO2023028539A1 (en) * | 2021-08-24 | 2023-03-02 | City Of Hope | Nk cells expressing il-15 and checkpoint inhibitors for the treatment of cancer |
| KR20230032557A (ko) * | 2021-08-31 | 2023-03-07 | 주식회사 이뮤노로지컬디자이닝랩 | Baff 세포외 도메인을 포함하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
| CA3231445A1 (en) * | 2021-09-16 | 2023-03-23 | Martin Schroeder | B7-h3 targeting fusion proteins and methods of use thereof |
| WO2023091954A2 (en) * | 2021-11-19 | 2023-05-25 | The Trustees Of The University Of Pennsylvania | Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy |
| US20230210900A1 (en) * | 2022-01-04 | 2023-07-06 | Kyverna Therapeutics, Inc. | Methods for treating autoimmune diseases |
| EP4272754A1 (en) | 2022-05-04 | 2023-11-08 | Universitätsklinikum Hamburg-Eppendorf | Method for producing cells expressing a chimeric antigen receptor (car) |
| US20250295773A1 (en) * | 2022-05-10 | 2025-09-25 | Miltenyi Biotec B.V. & Co. KG | Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy |
| WO2024026455A2 (en) * | 2022-07-29 | 2024-02-01 | Shoreline Biosciences, Inc. | Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages |
| EP4487868A1 (en) | 2023-07-06 | 2025-01-08 | Universitätsklinikum Hamburg-Eppendorf | Modified nk cell expressing a chimeric antigen receptor |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072372A1 (en) * | 2023-09-26 | 2025-04-03 | The General Hospital Corporation | Car-t cells expressing vegf binding proteins |
| CN117050195B (zh) * | 2023-10-13 | 2023-12-19 | 旭和（天津）医药科技有限公司 | 一种靶向baffr嵌合抗原受体、car-t细胞和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| JP4596916B2 (ja) | 2002-09-05 | 2010-12-15 | メディミューン，エルエルシー | Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20080299042A1 (en) | 2004-04-30 | 2008-12-04 | Biogen Idec Ma Inc. | Membrane Associated Molecules |
| US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2441846A3 (en) * | 2006-01-09 | 2012-07-25 | The Regents Of the University of California | Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy |
| CA2655471C (en) | 2006-06-12 | 2017-02-14 | Centocor, Inc. | Method for detecting il-16 activity and modulation of il-16 activity based on rantes proxy levels |
| EP2078040B1 (en) | 2006-11-02 | 2017-06-28 | Daniel J. Capon | Methods of producing hybrid polypeptides with moving parts |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| PL3006459T3 (pl) * | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| CA2739608A1 (en) * | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| EP2429584A4 (en) | 2009-05-13 | 2013-02-20 | Genzyme Corp | TREATMENT PROCEDURE AND COMPOSITIONS |
| BRPI1013927A2 (pt) | 2009-05-13 | 2016-04-05 | Genzyme Corp | métodos e composições para o tratamento de lúpus |
| EP2325322A1 (en) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retroviral vector particles and methods for their generation and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3102782A1 (en) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| JP5932970B2 (ja) | 2011-04-06 | 2016-06-08 | サンバイオ，インコーポレイティド | 末梢免疫機能を調節するための方法及び組成物 |
| BR112014004168A2 (pt) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| AU2012317395B2 (en) * | 2011-09-30 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
| US9447194B2 (en) * | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| KR20140127816A (ko) | 2012-02-22 | 2014-11-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법 |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| MX370148B (es) | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| AU2014214850C1 (en) * | 2013-02-06 | 2018-12-06 | Celgene Corporation | Modified T lymphocytes having improved specificity |
| KR102064230B1 (ko) | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| US9745368B2 (en) * | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| MX374681B (es) * | 2013-05-13 | 2025-03-06 | Cellectis | Receptor quimérico de antígeno específico para cd19 y sus usos. |
| CN105408473B9 (zh) * | 2013-05-14 | 2021-09-17 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
| JP6136650B2 (ja) * | 2013-06-28 | 2017-05-31 | ブラザー工業株式会社 | カートリッジ |
| CA2920539C (en) * | 2013-08-08 | 2024-01-02 | Cytune Pharma | Combined pharmaceutical composition |
| CN105873952A (zh) | 2013-10-31 | 2016-08-17 | 弗莱德哈钦森癌症研究中心 | 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途 |
| PE20160724A1 (es) | 2013-11-04 | 2016-08-04 | Glenmark Pharmaceuticals Sa | Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t |
| RU2717984C2 (ru) | 2013-11-21 | 2020-03-27 | ЮСиЭл БИЗНЕС ЛТД | Клетка |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| EP3102236A4 (en) * | 2014-02-05 | 2017-08-30 | The University of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| PT3105317T (pt) | 2014-02-14 | 2019-02-27 | Cellectis | Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas |
| WO2015124715A1 (en) * | 2014-02-21 | 2015-08-27 | Cellectis | Method for in situ inhibition of regulatory t cells |
| RU2016143389A (ru) * | 2014-04-10 | 2018-05-15 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом |
| US10301370B2 (en) * | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
| DE112014006656B4 (de) | 2014-05-14 | 2018-05-17 | Carsgen Therapeutics Limited | Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| MY189028A (en) * | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| DK4074735T3 (da) | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| CA2964785A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| KR102376242B1 (ko) * | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| SG10201913682QA (en) | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| JP6976960B2 (ja) * | 2015-11-27 | 2021-12-08 | カーサリクス プロプライエタリー リミテッド | 遺伝子改変された細胞およびその使用 |
| JP2019513347A (ja) * | 2016-03-04 | 2019-05-30 | ノバルティス アーゲー | 複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用 |
| GB201610512D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| MY200337A (en) * | 2016-10-07 | 2023-12-20 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain |
-
2016
- 2016-12-22 EP EP23220747.2A patent/EP4353750A3/en not_active Withdrawn
- 2016-12-22 US US16/312,769 patent/US20200283534A1/en not_active Abandoned
- 2016-12-22 JP JP2018567062A patent/JP7114490B2/ja active Active
- 2016-12-22 CA CA3029197A patent/CA3029197A1/en active Pending
- 2016-12-22 EP EP16906492.0A patent/EP3474867A4/en active Pending
- 2016-12-22 CN CN201680087034.6A patent/CN109562126A/zh active Pending
- 2016-12-22 WO PCT/US2016/068349 patent/WO2017222593A1/en not_active Ceased
-
2017
- 2017-06-21 US US15/538,620 patent/US11820819B2/en active Active
-
2022
- 2022-08-01 US US17/878,339 patent/US20230340113A1/en active Pending
-
2023
- 2023-10-13 US US18/379,708 patent/US20240141041A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522973A5 (enExample) | ||
| JP2018518974A5 (enExample) | ||
| Birkholz et al. | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | |
| JP7300763B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Li et al. | Preclinical and clinical studies of CAR-NK-cell therapies for malignancies | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| JP2017513470A5 (enExample) | ||
| Morgan et al. | Engineering CAR-T cells for improved function against solid tumors | |
| JP2020074776A5 (enExample) | ||
| JP2019528769A5 (enExample) | ||
| Klein et al. | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | |
| AU2014407540B2 (en) | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation | |
| Waldmann | The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy | |
| Bien et al. | Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review | |
| JP2021019589A5 (enExample) | ||
| CN105175544B (zh) | 一种抗pd-1人源化单克隆抗体及其应用 | |
| JP2017515464A5 (enExample) | ||
| JP2020533301A5 (enExample) | ||
| JP2019500012A5 (enExample) | ||
| JP2020517259A5 (enExample) | ||
| JP2020513828A5 (enExample) | ||
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2018522567A5 (enExample) | ||
| CN110099923A (zh) | 配对改善的t细胞受体 | |
| JP2018519356A5 (enExample) |